Citius Pharma Q3 net loss $10.6M; FDA approves LYMPHIR, oncology spin-off begins trading

Citius Pharmaceuticals, Inc.

2025-Q3 EPS reported -$4.37 vs consensus -$0.50 ▼ miss (-780.3%)

FDA approved LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma on Aug 12, 2024.
Oncology subsidiary merged with TenX Keane; Citius Oncology (Nasdaq: CTOR) starts trading Aug 13, 2024.
Mino-Lok Phase 3 trial met primary and secondary endpoints; cash $17.9M as of June 30, 2024, with runway through Dec 2024.
Net loss $10.6M ($0.06/sh) for Q3 ended June 30, 2024, vs $8.5M ($0.06/sh) a year ago; R&D expenses $2.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.